Dissociative Identity Disorder (DID): psilocybin research evidence

Why this category is marked negative

DID involves identity fragmentation, amnesia barriers, and structural dissociation rooted in complex trauma. Psilocybin reliably loosens self-boundaries and can resurface overwhelming material. In that context, current clinical practice treats DID as a high-risk exclusion rather than a therapeutic target, and PSILORIS finds no condition-specific efficacy evidence that would reverse that stance.

What the evidence currently is (and is not)

• There is no dedicated modern psilocybin RCT or open-label efficacy trial for DID in the curated set.
• Contemporary protocols often list DID as an explicit exclusion. The Meshkat et al. (2025) psilocybin-assisted massed CPT PTSD protocol (and matching ClinicalTrials.gov record NCT06386003) excludes history or current primary DID alongside psychosis-spectrum diagnoses.
• Purcell, Lebois, Kaufman and colleagues (2024) review DID treatment and neurobiology with a focus on empirically supported psychotherapy and limited pharmacology for related dissociative symptoms — not psychedelic dosing as standard care.
• Rougemont-Bücking et al. (2024) argue theoretically that psychedelic-augmented psychotherapy might help resolve traumatic dissociation via the structural dissociation model (apparently normal vs emotional personality parts). That paper is mechanistic and phenomenological; it is not a DID efficacy trial.
• Elfrink & Bergin (2025) propose psychedelic iatrogenic structural dissociation (PISD): psychedelics may reactivate dissociated traumatic material, disrupt ANP/EP balance, and increase risk of identity fragmentation, derealization, and lasting adverse effects — especially after early trauma — unless trauma-informed screening, preparation, and integration are in place.
• Broader safety and adverse-psychiatric literature (Johnson et al., 2008; Yildirim et al., 2024) supports careful psychiatric screening for vulnerability; DID-specific outcome data remain essentially absent.

How to read the theoretical tension

Optimistic PAP writing about traumatic dissociation and cautionary PISD writing share the same structural-dissociation vocabulary. One frames psychedelics as a possible integration catalyst under specialised care; the other frames them as a possible destabiliser. Neither substitutes for controlled DID trials. Until those exist, the practice signal (trial exclusion + absence of efficacy data) outweighs speculative therapeutic claims for DID itself.

How to read "negative" on PSILORIS

Negative means the balance of evidence and risk currently argues against therapeutic use for this indication, not that every related research question is forever closed. Any future exception would require specialised, trauma-informed protocols far beyond general educational guidance.

Safety emphasis

Unsupervised self-administration of psilocybin by people with DID (or suspected complex dissociative disorders) is particularly high risk and is not endorsed by PSILORIS. Ego-dissolution and trauma reactivation can be difficult to distinguish from, or may worsen, baseline identity disruption and dissociation. People seeking care for DID should work with clinicians experienced in dissociative disorders; standard phase-oriented psychotherapy remains the evidence-based path described in current DID treatment reviews.